Back to discover
Disease

Neovascularization, Pathologic

Clinical development underwayActively researchedCooling momentum
36
Publications
1
Clinical trials
8
Related conditions
10
Related proteins
2025
Latest publication
Current focus
Bevacizumab biologyNeoplasm biologyTherapeutic developmentInflammation & immunityDisease mechanisms & pathology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Pathological angiogenesis was associated with cerebrovascular lesion and neurodegeneration in Alzheimer's disease.

Research2025-01-08Alzheimer's & dementia : the journal of the Alzheimer's Association

Pre-metastatic niche: formation, characteristics and therapeutic implication.

Research2024-09-25Signal transduction and targeted therapy

Angiogenic signaling pathways and anti-angiogenic therapy for cancer.

Research2023-05-11Signal transduction and targeted therapy

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

1 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
1
All trials
0
Active
0
Late-stage
1
Completed

Research activity

36 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20022025
Most influential

Lung cancer.

The New England journal of medicine · 2008 · 1,978 cites

The inflammatory response in myocardial infarction.

Cardiovascular research · 2002 · 1,484 cites

Tumor angiogenesis: causes, consequences, challenges and opportunities.

Cellular and molecular life sciences : CMLS · 2020 · 1,371 cites
Recent publications
Major themes8
  • Neoplasms11
  • Tumor Microenvironment7
  • Neovascularization, Pathologic5
  • Vascular Endothelial Growth Factor A4
  • Angiogenesis Inhibitors3
  • Immune Checkpoint Inhibitors2
  • Signal Transduction2
  • Alzheimer Disease1
Leading journals6
  • Frontiers in immunology6
  • Angiogenesis3
  • Signal transduction and targeted therapy3
  • Genes & development2
  • International journal of molecular sciences2
  • The Journal of clinical investigation2
Leading researchers8
  • Bachoo RM2
  • Cavenee WK2
  • DePinho RA2
  • Duda DG2
  • Furnari FB2
  • Griffioen AW2
  • Heymach JV2
  • Jain RK2
Affiliations (unnormalised)6
  • Angiogenesis Laboratory3
  • Immunology Research Center2
  • School of Medicine2
  • Tabriz University of Medical Sciences2
  • Ahvaz Jundishapur University of Medical Sciences1
  • Aldo Moro University of Bari1

Disease biology

10 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

8 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Pathologic neovascularization is the proliferation of blood vessels in tissues where vessel growth is abnormal or occurs in an abnormal location. The supplied literature frames it as a form of pathological angiogenesis, especially in tumors and other disease settings.

Causes

The grounding supports hypoxia as a major inducer of VEGF gene transcription, linking low oxygen states to abnormal vessel growth. It also indicates that pathological angiogenesis is mediated by VEGF and related signaling factors in disease tissues, particularly tumors.

Pathophysiology

The process is driven by angiogenic signaling, especially VEGF acting through its high-affinity receptors VEGFR-1 and VEGFR-2. The literature also connects it to signal transduction, the tumor microenvironment, cytokines, lymphokines, hypoxia-inducible factor 1, epithelial-mesenchymal transition, and contributions from non-endothelial cells in tumors.

Risk factors

Hypoxia is a supported factor associated with induction of VEGF and pathological angiogenesis. The grounding also supports association with tumor settings, including the tumor microenvironment and malignant neoplasms, where abnormal vessel growth is commonly studied.

Current standard of care

The supplied reviews support anti-angiogenic therapy as the main treatment category, including anti-VEGF monoclonal antibodies and tyrosine kinase inhibitors. Bevacizumab is specifically co-studied, and the literature also notes that these approaches are used in cancer care, though benefit may be modest and resistance can occur.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.